Chris explains the complex relationship between ACE inhibitors and ACE two receptors, shedding light on their impact on angiotensin II levels and potential effects on COVID-19. The discussion challenges the common assumptions about ACE inhibitors and their role in managing disease risk, emphasizing the need for individualized approaches.
